Join
Live feed
·
NEWSReleasevia Quantisnow
Ampio Pharmaceuticals Inc. logo

Ampio Says Efficacy Results From Recently Completed Nonclinical Pre-IND Enabling Studies With OA-201 Do Not Support An IND Submission Which Was Anticipated In Early 2025

ByQuantisnow·Wall Street's wire, on your screen.
AMPE· Ampio Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AMPE (Ampio Pharmaceuticals Inc.) and more on Quantisnow.

Ampio Says Efficacy Results From Recently Completed Nonclinical Pre-IND Enabling Studies With OA-201 Do Not Support An IND Submission Which Was Anticipated In Early 2025 | Quantisnow